Nav: Home

Experimental drug combination shows potential for triple-negative breast cancer

March 11, 2020

Researchers from Vanderbilt-Ingram Cancer Center discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.

Although there is no way to currently target MYCN directly, investigators from the Pietenpol laboratory determined that experimental drugs called BET inhibitors are effective against TNBCs in model systems that overexpress MYCN, especially when coupled with the inhibition of MEK, another known oncogene. MYCN is a well-known oncogene that plays a role in cancer aggressiveness, but it is typically associated with neuronal and neuroendocrine cancers.

The research, published in Science Translational Medicine, sets the stage for clinical trials and a potential treatment for TNBCs with the MYCN oncogene. The study is the cover story of the March 11 issue of the journal. It's based on the dissertation work of Vanderbilt graduate student and first author Johanna Schafer, PhD, whose brother designed the issue's cover art. Schafer did her graduate research in the lab of Jennifer Pietenpol, PhD, the Benjamin F. Byrd Jr. Professor of Oncology and the study's senior author.

TNBC is a particularly difficult type of breast cancer to treat. Although it represents about 15% of breast cancers, TNBC accounts for about 25% of all breast cancer-related deaths. Treatment options for many patients are still limited to chemotherapy.

"This study provides pre-clinical data for investigation of the potential utility of MEK and BET inhibitors in advanced triple-negative breast cancer," said Pietenpol, Vanderbilt-Ingram director, Executive Vice President for Research at Vanderbilt University Medical Center and holder of the Brock Family Directorship in Career Development. "As a next step, our research team is proposing the further development and clinical trials of this combination therapy."

A number of MEK inhibitors have already been approved by the U.S. Food and Drug Administration. BET inhibitors are a class of compounds currently under clinical development.

Elevated MYCN expression had previously been observed in tumors of the nervous system and non-neuronal tumors, such as neuroendocrine and prostate cancer, hematological malignancies and small cell lung cancers. The study found MYCN is heterogeneously expressed within a substantial fraction of TNBCs and in a higher rate of cases that don't respond to chemotherapy.
-end-
The research was supported by National Cancer Institute grants CA098131 (Breast SPORE), CA068485 and CA211206; a grant from Incyte Corporation as part of the Incyte-Vanderbilt Alliance and by Susan G. Komen (SAC110030), a major funder of metastatic breast cancer research.

Vanderbilt University Medical Center

Related Breast Cancer Articles:

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.
Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.
Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.
Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.
Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.
Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.
Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
More Breast Cancer News and Breast Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.